B-cell malignancies

B-cell malignancies include most non-Hodgkin lymphomas (NHL), some leukaemias, and myelomas.1

B-cell signalling

Insights into key pathways have helped identify new targets for treating B-cell malignancies.2-5


Click here to access our resources section, which contains a range of useful documents and links with more information about B-cell malignancies.

B-cell signalling

Click below to download the B-cell malignancies brochure.

/sites/default/files/DA Brochure.pdf
  1. Mitchell M et al. A multisource approach to improving epidemiologic estimates: application to global B-cell malignancies. ISRN Oncol. 2012;2012:129713.
  2. Kil LP et al. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71-83.
  3. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119-132.
  4. Burger JA et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
  5. ten Hacken E, Burger J. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia - focus on the B cell receptor. Clin Cancer Res. 2014;20(3):548-556